Heinzlef O, Cohen A, Amarenco P
Hôpital Tenon, Paris.
Rev Neurol (Paris). 2001 Jul;157(6-7):619-31.
There is mounting evidence to implicate complex atherosclerotic aortic plaques as a significant independent risk factor for embolic stroke. Ulcerated plaques at autopsy, plaques thicker than 4 to 5mm at transesophageal echocardiography and those with mobile components are more likely to be associated with stroke. Mobile thrombus in the lumen may be a source of cerebral emboli. Among patients with ischemic stroke, those with plaques thicker than 4mm in the aortic arch have the highest risk of recurrent stroke, myocardial infarction, other vascular event including vascular death. However, since no randomized trials have been conducted to evaluate the role of any antithrombotic therapies in patients with aortic atheroma, no recommendation can be made regarding the best treatment strategies. Antiplatelet agents, oral anticoagulant, thrombolytic therapy, and elective surgical endarterectomy or graft replacement are all reasonable options that have been proposed and that must be evaluated in term of benefit/risks ratio in specific randomized controlled trials. Meanwhile, antiplatelet agents and aggressive risk factor management appear to be the first line treatment. No recommendation can be made to use oral anticoagulation in these patients nor for a target INR. Concerns also exist on the possibility of anticoagulation driven cholesterol embolism in these patients.
越来越多的证据表明,复杂的动脉粥样硬化性主动脉斑块是栓塞性中风的一个重要独立危险因素。尸检时发现的溃疡性斑块、经食管超声心动图显示厚度超过4至5毫米的斑块以及含有可移动成分的斑块更有可能与中风相关。管腔内的移动血栓可能是脑栓塞的来源。在缺血性中风患者中,主动脉弓处斑块厚度超过4毫米的患者发生复发性中风、心肌梗死及包括血管性死亡在内的其他血管事件的风险最高。然而,由于尚未进行随机试验来评估任何抗血栓治疗在主动脉粥样硬化患者中的作用,因此无法就最佳治疗策略给出建议。抗血小板药物、口服抗凝药、溶栓治疗以及选择性外科动脉内膜切除术或血管移植置换术都是已被提出的合理选择,必须在特定的随机对照试验中根据效益/风险比进行评估。同时,抗血小板药物和积极的危险因素管理似乎是一线治疗方法。对于这些患者,不建议使用口服抗凝药,也不建议设定目标国际标准化比值(INR)。这些患者还存在抗凝导致胆固醇栓塞的可能性。